Zeenat Qureshi Stroke Research Center, University of Minnesota, Minneapolis, Minnesota 55455, USA.
AJNR Am J Neuroradiol. 2013 Feb;34(2):354-9. doi: 10.3174/ajnr.A3202. Epub 2012 Jul 19.
Endovascular treatment for acute ischemic stroke consists of various mechanical and pharmacologic modalities used for recanalization of arterial occlusions. We performed this study to determine the relationship among procedure time, recanalization, and clinical outcomes in patients with acute ischemic stroke undergoing endovascular treatment.
We analyzed data from consecutive patients with acute ischemic stroke who underwent endovascular treatment during a 6-year period. Demographic characteristics, NIHSS score before and 24 hours after the procedure, and discharge mRS score were ascertained. Procedure time was defined by the time interval between microcatheter placement and recanalization or completion of the procedure. We estimated the procedure time after which favorable clinical outcome was unlikely, even after adjustment for age, time from symptom onset, and admission NIHSS scores.
We analyzed 209 patients undergoing endovascular treatment (mean age, 65 ± 16 years; 109 [52%] men; mean admission/preprocedural NIHSS score, 15.3 ± 6.8). Complete or partial recanalization was observed in 176 (84.2%) patients, while unfavorable outcome (mRS 3-6) was observed in 138 (66%) patients at discharge. In univariate analysis, patients with procedure time ≤30 minutes had lower rates of unfavorable outcome at discharge compared with patients with procedure time ≥30 minutes (52.3% versus 72.2%, P = .0049). In our analysis, the rates of favorable outcomes in endovascularly treated patients after 60 minutes were lower than rates observed with placebo treatment in the Prourokinase for Acute Ischemic Stroke Trial. In logistic regression analysis, unfavorable outcome was positively associated with age (P = .0012), admission NIHSS strata (P = .0017), and longer procedure times (P = .0379).
Procedure time in patients with acute ischemic stroke appears to be a critical determinant of outcomes following endovascular treatment. This highlights the need for procedure time guidelines for patients being considered for endovascular treatment in acute ischemic stroke.
急性缺血性脑卒中的血管内治疗包括各种用于动脉闭塞再通的机械和药物治疗方法。我们进行这项研究旨在确定接受血管内治疗的急性缺血性脑卒中患者的治疗时间、再通率和临床结局之间的关系。
我们分析了在 6 年期间接受血管内治疗的连续急性缺血性脑卒中患者的数据。确定了人口统计学特征、治疗前后 NIHSS 评分和出院 mRS 评分。治疗时间定义为微导管放置到再通或完成治疗的时间间隔。我们估计了即使在调整年龄、症状发作时间和入院 NIHSS 评分后,不太可能获得良好临床结局的治疗时间。
我们分析了 209 例接受血管内治疗的患者(平均年龄 65±16 岁,109[52%]为男性,平均入院/术前 NIHSS 评分 15.3±6.8)。176 例(84.2%)患者观察到完全或部分再通,138 例(66%)患者出院时预后不良(mRS 3-6)。单因素分析显示,治疗时间≤30 分钟的患者出院时预后不良的发生率低于治疗时间≥30 分钟的患者(52.3%与 72.2%,P=0.0049)。在我们的分析中,治疗时间 60 分钟后血管内治疗患者的良好结局发生率低于急性缺血性脑卒中患者的普洛雷辛溶栓试验中的安慰剂治疗。Logistic 回归分析显示,预后不良与年龄(P=0.0012)、入院 NIHSS 分层(P=0.0017)和较长的治疗时间(P=0.0379)呈正相关。
急性缺血性脑卒中患者的治疗时间似乎是血管内治疗后结局的关键决定因素。这突出了需要为考虑接受血管内治疗的急性缺血性脑卒中患者制定治疗时间指南。